Pharmacological Treatment and Emerging Therapies on Hyperlipidemia

Abstract

Angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (Apo C-III) and their functions in cardiovascular health and lipid metabolism. The liver's production of Apo C-III prevents triglyceride-rich lipoproteins from breaking down, which raises triglyceride levels and raises the risk of cardiovascular disease. Those who have mutations that cause the APOC3 gene to malfunction have much lower triglyceride levels and a lower chance of developing ischemic heart disease. In an effort to mimic the protective effects observed in APOC3 deficiency, treatments that target Apo C-III, such as plozasiran, olezarsen, and volanesorsen, have been developed. As a therapeutic target, ANGPTL3 has also been identified, and evinacumab, a monoclonal antibody, is currently being used in clinical settings. To completely comprehend the effectiveness and safety of these novel treatments, further extensive long-term research is necessary.